Infliximab is a chimeric monoclonal antibody that binds to both soluble and membrane-bound TNF-α, approved by the Food and Drug Administration (FDA) for treating IBD patients [45,50,126]. This evidence concerns the gene TNF and inflammatory bowel disease.